Treatment of patients with hematologic neoplasm, fever, and neutropenia.
Choices of empirical antibiotic therapy for patients with febrile neutropenia must be made with very little information about the source and site of infection. The clinician is aided by recognition of the subtle signs and symptoms of infection in immunocompromised patients. National guidelines should be applied according to the microbiological patterns and trends in drug resistance at each institution. Case studies are provided to illustrate these challenges in daily practice.
Sepkowitz
Kent A
KA
Infectious Disease Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. sepkowik@mskcc.org
D000328:Adult; D000553:Ambulatory Care; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis; D016470:Bacteremia; D002177:Candidiasis; D002675:Child, Preschool; D024881:Drug Resistance, Bacterial; D021902:Enterobacter aerogenes; D004756:Enterobacteriaceae Infections; D020345:Enterocolitis, Necrotizing; D005260:Female; D005334:Fever; D016469:Fungemia; D019337:Hematologic Neoplasms / Q000276:immunology* / Q000628:therapy; D006760:Hospitalization; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D009503:Neutropenia; D009894:Opportunistic Infections / Q000188:drug therapy* / Q000517:prevention & control; D012772:Shock, Septic; D013290:Streptococcal Infections; D034363:Viridans Streptococci
D000900:Anti-Bacterial Agents